Coherus Oncology (CHRS) FCF Margin Growth (3y) (2016 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) FCF Margin Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -2,024.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1,067.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -1,272.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -2,228.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -5,426.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4,612.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -203.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.75 Mn |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -36,754.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36,754.00 |
| Mar 31, 2026 | -25,787.00 |
| Dec 31, 2025 | 22.00 |
| Sep 30, 2025 | -31,782.00 |
| Jun 30, 2025 | 434,414.00 |
| Mar 31, 2025 | -31,104.00 |
| Dec 31, 2024 | 44,192.00 |
| Sep 30, 2024 | -104,102.00 |
| Jun 30, 2024 | 96,936.00 |
| Mar 31, 2024 | 611,018.00 |
| Dec 31, 2023 | -4,331.00 |
| Sep 30, 2023 | -11,266.00 |
| Jun 30, 2023 | -10,905.00 |
| Mar 31, 2023 | -22,243.00 |
| Dec 31, 2022 | -23,457.00 |
| Sep 30, 2022 | -13,103.00 |
| Jun 30, 2022 | -9,962.00 |
| Mar 31, 2022 | 6,357.00 |
| Jun 30, 2020 | 408,082.00 |
| Mar 31, 2020 | 4.66 Mn |